Unraveling The Unknowns: Process Development Considerations For Next-Gen RNA Therapeutics

As additional mRNA therapeutics makers progress toward and into the clinic, we've begun to gather more knowledge about what makes our mRNA products "tick," and how our processes impact the overall quality of our products.

This Advancing RNA Live panel discussion will continue to dig into the current known unknowns (and unknown unknowns) about our mRNA therapeutics candidates that make adopting the traditional QbD approach complicated in the mRNA therapeutics space today.

In particular, this panel will showcase some of the considerations most important to those working with next-gen therapeutics approaches—namely gene editing, epigenome editing, and alternative formulations of mRNA.